FDA Investigator Jean M Kelahan

Jean M Kelahan has conducted inspections on 89 sites in 2 countries as of 27 Jun 2024. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
89
Last Inspection Date:
27 Jun 2024
Investigator Role:
FDA Investigator
Redica ID:
100005192
Countries of Inspections:
United States of America, India
FDA Investigators that have inspected at least one site in common with Jean M Kelahan:
Addam S Reynolds, Alberto A Viciedo, Allen Lou, Althea A Williams, Amy L Singer, Amy M Codella, Amy M Cramer, Ana S Cabrera, Anastasia I Offordile, Ann Marie Montemurro, Ann Marie Schofield, Annemarie B Randow, Annemarie Bodnar, Arindam Dasgupta, PhD, Atul J Agrawal, Barbara D Wright, Barbara Jwilimczyk Macri, Barbara L Rellahan, PhD, Burnell M Henry, Byungja E Marciante, Cara M Minelli, Cary Greene, Charles J Chacko, Cheryl A Grandinetti, Christian D Lynch (CDL), Christina N Maurino, Christine M Cerenzio, Christopher J Adams, Creighton T Tuzon, Daniel J Grabicki, Darin S Wiegers, David H Smith, Dawn L Wydner, Deborah B Nixon, Denise M Visco, Investigator, Dennis E Guilfoyle, PhD, Dhaval H Patel, Dolores Harper, Donald L Lech, Doreen P Gubbay, Dorothy J Denes, Douglas C Kovacs, Dr. Guang Gao, PhD, Dr. Zhou Chen (nmi), MD PhD, Edward D Mcdonald, Edward O'shaughnessy, Eliezar Ramos, Emest F Bizjak, Emily A Walters, Emmanuel Jramos Maldonado, Eric J Cunningham, Eric Rothschild, Erin D Mccaffery, Esteban Beltran, Eufemia G Gonzalez, Frank J Marciniak, Gene D Arcy, George Pyramides, Gobiga Vanniyasingam, Guerlain Ulysse, Helen B Ricalde, Helen Verdel, J David Doleski, Jacqueline A O'shaughnessy, PhD, Jacqueline Mdiaz Albertini, Jacqueline S Warner, James E Frye, Jean Blackston Hill, Jennifer A Bazergui, Jennifer L Custodio, Jennifer Macmillan, Jessica M Monteiro, Joan A Loreng, Joanne Pryzbylik, Jonee J Mearns, Joseph F Mcginnis, RPh, Joseph L Despins, PhD, Joy Rkozlowski Klena, Juanita P Versace, Julie D Bringger, Kara A Scheibner, PhD, Karen E D'orazio, Karen F Tomaziefski, Kassa Ayalew, MD, Keith M Reilly, Kelli F Dobilas, Kelly I Anderson, Kelly L Anderson, Kimberly M Bigler, Kinh Q Mac, Kish Bolden, Kristen E Rescigno, Kristina L Conroy, Kristy A Zielny, Krystal O Ogunremi, Kwong P Lee, Kyle D Covill, Lata C Mathew, PhD, Lauren L Vajo, LCDR Debra Emerson, Lenahan Lenahan, Peter R, Li Li, Liatte Kreuger, PharmD, Lisa Harlan, Lisa Mathew, Loretta Nemchik, Marcelo O Mangalindan, Jr, Margaret M Sands, Maria Estrella, Marion Michaelis, Mariza M Jafary, Martha T Olone, Martin K Yau, PhD, Mary T Carden, Matthew A Spataro, Mayar M Mussa, Meihong Liu, Melba Trivera Clavell, Melissa A Freeman, Melissa A Zuppe, Melissa T Roy, Meredith L Sheridan, Meyer J Slobotsky, Michael F Skelly, PhD, Michael J Nerz, Michael R Klapal, Michael Serrano, Michael Skelly, Mike M Rashti, Mohsen Rajabi Abhari, FDA, Monica L Gutierrez, Monika Borkowska, Nancy F Scheraga, Nancy L Rolli, Nancy M Espinal, Nerizza B Dalena, Nerizza B Guerin, Nicholas A Violand, Nina Yang, Niraj R Mehta, PhD, Nisha C Patel, Omotunde O Osunsanmi, Paul L Bellamy, Paula A Trost, Peter R Lenahan, Prabhu P Raju, Qiao Y Bobo, Regina T Brown, Richard D Manney, Richard T Riggie, Robert G Ruff, Robert Jennings, Rodney T Allnutt, Rose Ashley, Russell J Glapion, Sandra Kershaw, Sarah Adella Fave, Sarah Forney, Schultz, Sherri J Liu, Sheryl A Kochman, Shirley H Isbill, Shirley S Wen, Sidney B Priesmeyer, Simone E Pitts, Sinai I Davis, Stephanie T Durso, Stephen D Brown, Susan M Jackson, Susan T Hadman, Tania E Garcia, Tania E Vizcaino, Tara G Bizjak, Tara R Gooen, Tawny L Colling, Teresita C Mercado, Thomas J Arista, Tonia F Bernard, Tyanna N Hadley, Valerie C Reed, Valerie Reed, Wayne J Meyer, Willy A Orantes, Xiaohan Cai, PhD, Xiaoping Guan, Yvesna C Blaise, Zakaria I Ganiyu

Jean M Kelahan's Documents

Publish Date Document Type Title
May, 2002 FDA 483 Sanofi-Aventis U.S. LLC - Form 483, 2002-05-20
June, 2003 EIR Integra LifeSciences Corporation - EIR, 2003-06-19
August, 2000 EIR Nelson Laboratories Fairfield Inc. - EIR, 2000-08-03
April, 2001 FDA 483 Bayshore Comm Hosp - Form 483, 2001-04-24
April, 2003 FDA 483 Boghossian, Jack MD - Form 483, 2003-04-04
November, 2000 FDA 483 Rubin Arnold D Md - Form 483, 2000-11-01
October, 2003 EIR Excelsior Medical LLC - EIR, 2003-10-17
November, 2000 EIR Rubin Arnold D Md - EIR, 2000-11-01
March, 2002 EIR Syneos Health Clinical, Inc. - EIR, 2002-03-13
January, 2003 EIR Hoffmann La Roche Inc - EIR, 2003-01-09
May, 2001 EIR Bayer HealthCare LLC - EIR, 2001-05-18
December, 2003 FDA 483 Cordis Corporation - Form 483, 2003-12-04
August, 2007 EIR Labcorp Early Development Laboratories, Inc. - EIR, 2007-08-23
March, 2000 FDA 483 Response Merck, Inc. - Form 483R, 2000-04-07
April, 2003 EIR Boghossian, Jack MD - EIR, 2003-04-04
January, 2001 FDA 483 Response Zeus Scientific, Inc. - Form 483R, 2001-02-06
September, 1997 EIR Jeffrey Apter, M.D. - EIR, 1997-09-24
October, 2003 FDA 483 Excelsior Medical LLC - Form 483, 2003-10-17
May, 2000 FDA 483 Response Princeton Medical Institute - Form 483R, 2000-05-15
March, 2000 EIR Merck, Inc. - EIR, 2000-03-27
August, 2002 EIR Ingenix Pharmaceutical Services - EIR, 2002-08-15
August, 2003 FDA 483 Response Labcorp Early Development Laboratories, Inc. - Form 483R, 2003-08-19
April, 2001 FDA 483 Response Bayshore Comm Hosp - Form 483R, 2001-07-12
April, 2000 EIR Jeffrey Apter, M.D. - EIR, 2000-04-11
August, 2003 FDA 483 Labcorp Early Development Laboratories, Inc. - Form 483, 2003-08-06
January, 2003 FDA 483 Hoffmann La Roche Inc - Form 483, 2003-01-09
May, 2000 FDA 483 Princeton Biomedical Research, P.A. - Form 483, 2000-05-03
August, 2005 FDA 483 Response Shelhigh, Inc. - Form 483R, 2005-08-30
December, 2003 FDA 483 Response Cordis Corporation - Form 483R, 2003-12-22
August, 2000 FDA 483 Nelson Laboratories Fairfield Inc. - Form 483, 2000-08-03
March, 2001 FDA 483 Elliot Frank Md - Form 483, 2001-03-26
May, 2003 EIR Cordis Corporation - EIR, 2003-05-19
January, 2003 FDA 483 Response Hoffmann La Roche Inc - Form 483R, 2003-01-27
May, 2003 FDA 483 Cordis Corporation - Form 483, 2003-05-19
March, 2001 EIR Elliot Frank Md - EIR, 2001-03-26
August, 2002 FDA 483 Ingenix Pharmaceutical Services - Form 483, 2002-08-15
December, 2003 EIR Sanofi-Aventis U.S. LLC - EIR, 2003-12-08
August, 2007 FDA 483 Response Labcorp Early Development Laboratories, Inc. - Form 483R, 2007-09-06
April, 2003 FDA 483 Response Labcorp Drug Development - Form 483R, 2003-05-21
August, 2003 EIR Labcorp Early Development Laboratories, Inc. - EIR, 2003-08-06
April, 2001 EIR Bayshore Comm Hosp - EIR, 2001-04-24
September, 2004 FDA 483 Diopsys, Inc. - Form 483, 2004-09-02
March, 2000 FDA 483 Merck, Inc. - Form 483, 2000-03-27
August, 2005 FDA 483 Shelhigh, Inc. - Form 483, 2005-08-10
March, 2003 EIR Denker, Michael M.D. - EIR, 2003-03-13
January, 2001 FDA 483 Zeus Scientific, Inc. - Form 483, 2001-01-31
March, 2001 FDA 483 Response Elliot Frank Md - Form 483R, 2001-03-26
August, 2002 FDA 483 Response Ingenix Pharmaceutical Services - Form 483R, 2002-08-29
September, 2003 EIR Labcorp Early Development Laboratories, Inc. - EIR, 2003-09-19
April, 2003 FDA 483 Response Boghossian, Jack MD - Form 483R, 2003-04-09
May, 2001 FDA 483 EUSA Pharma (USA) Inc. - Form 483, 2001-05-23
December, 2004 EIR Princeton Center for Clinical Research - EIR, 2004-12-13
May, 2000 EIR Princeton Medical Institute - EIR, 2000-05-03
April, 2003 EIR Labcorp Drug Development - EIR, 2003-04-23
May, 2002 EIR Sanofi-Aventis U.S. LLC - EIR, 2002-05-20

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more